Participants 58 84 6
myelodysplastic disorders.
Participants 229 274 7
patients with myelodysplastic syndromes (MDS)
Participants 276 331 8
Sixty-eight evaluable patients with MDS were randomized
Participants 931 1009 3
Approximately 30% of patients in both groups had progression of their disease,
Participants 1290 1310 4
in patients with MDS
